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The nucleotide and complete amino acid sequence for the human /82-glycoprotein I (/3,I) was derived by sequencing the
cDNA clone pB2I- 1. In addition to the 326 amino acid residues of the mature protein this clone codes for a putative leader
peptide and contains sequence representing 5' and 3' untranslated regions. When this amino acid sequence was compared
with the previously published primary sequence, three major amino acid substitutions were found, two involving cysteine
residues. These substitutions lead to a new alignment of the complement control protein (CCP) repeats present in fl2I and
a prediction of the complete disulphide bond organization. Northern-blot analysis indicates that hepatocytes are a major
site of biosynthesis for this protein. A transcription signal of about 1.5 kb was detected by using RNA from HepG2 cells.
INTRODUCTION
/#2-Glycoprotein I (V2I) is a protein of approx. 50 kDa that was
first described by Schultze et al. (1961). It is associated with
lipoproteins in plasma at a concentration of about 200 /sg/ml
(Polz & Kostner, 1979). The site of biosynthesis is not known.
The amino acid sequence of 1'21 was originally determined by
protein-sequencing techniques and is 326 residues in length
(Lozier et al., 1984). The sequence consists of five contiguous
repeating units, of about 60 amino acid residues, that belong to
the complement control protein (CCP) superfamily (Day et al.,
1989; Reid & Day, 1989). The CCP repeat is present in the
proteins involved in the regulation ofcomplement activation and
in a growing number of non-complement proteins, including
interleukin-2 receptor and a new family of leucocyte adhesion
molecules (Day et al., 1989).
Although the function of /321 has been investigated, no clear
physiological role has yet been determined. However, /321 has
been shown to bind to anionic phospholipids (Wurm, 1984),
platelets (Schousboe, 1980), heparin (Polz et al., 1979), DNA
(Kroll et al., 1976) and mitochondria (Schousboe, 1979). A
possible role of/321 is inhibition of the intrinsic blood coagulation
cascade by binding to negatively charged phospholipids on the
surface of damaged cells, thus preventing activation of the
pathway (Schousboe, 1985; Nimpf et al., 1986). Furthermore, it
inhibits both prothrombinase activity of activated platelets
(Nimpf et al., 1986) and ADP-mediated platelet aggregation
(Nimpf et al., 1987). McNeil et al. (1990) and Galli et al. (1990)
have demonstrated that anti-phospholipid antibodies, present in
certain autoimmune diseases (e.g. systemic lupus erythematosus),
are directed against an antigen consisting of a complex of l21 and
negatively charged phospholipids (cardiolipin).
As no structural information at the DNA level was available,
we have determined the complete cDNA sequence for /321 and
provide evidence for a site of biosynthesis.
EXPERIMENTAL
Polymerase chain reaction
Total RNA was isolated from an HepG2 human liver cell line
by using guanidinium thiocyanate extraction and a CsCl gradient
(Maniatis et al., 1982). A 10,ug portion was used for the first-
strand cDNA synthesis (cDNA synthesis kit; Amersham,
Aylesbury, Bucks., U.K.). One-tenth of this reaction mixture was
used for PCR amplification. The sequences of the synthetic
oligonucleotides used to amplify the /321 transcript were deduced
from the primary amino acid sequence (Lozier et al., 1984)
according to the human codon bias described by Lathe
(1985). The following oligonucleotides were generated by
using an Applied Biosystems 38-1A DNA synthesizer: sense
5'-GGCCGGACCTGCCCCAAGCCTGATGACCTGCCATT
and antisense 5'-GCATGGCTTCACATCGGAGGCATC-
TGTCTTCCA. Twenty-five cycles of amplification (1 min at
95 °C, 1 min at 60 °C and 3 min at 72 °C) were performed in a
100l jl reaction mixture [10 mM-Tris/HCl buffer, pH 8.3, con-
taining 50 mM-KCl, 1.5 mM-MgCl2, 0.01 % gelatin, 200 zm-
dNTP, 1 uM-5'-primer, 1 uM-3'-primer and 3 units of Thermus
aquaticus (Taq) polymerase (Perkin-Elmer Cetus)] covered with
1001ul of paraffin. A 5,1 portion of this reaction mixture was
analysed by electrophoresis on a 0.7% (w/v) agarose gel.
Isolation of 821 clones and cDNA sequencing
A human liver cDNA library constructed in the eukaryotic
expression vector CDM8 (Estaller et al., 1991) was screened with
the /321 PCR product (978 bp in length). Approx. 300000 colonies
were screened with the PCR probe, which had been labelled with
[c-32P]ATP by the polypriming method (Feinberg & Vogelstein,
1983). The length of the cDNA inserts from positive clones were
estimated by a PstI-HindIII restriction digest. The sequence of a
1.15 kb insert (designated clone pB2I-l) was determined from
both strands by using a double-strand T7Sequencing Kit
(Pharmacia, Milton Keynes, Bucks., U.K.). Segments of a further
six positive clones were also sequenced.
Northern-blot analysis
A 10 ,ug portion of total RNA was electrophoresed in a 1.2%
(w/v) agarose gel in Mops buffer containing 50% (v/v) form-
aldehyde (Maniatis et al., 1982). RNA was transferred to a
Hybond-N membrane (Amersham) and hybridized at 65 °C with
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the [a-32P]ATP-radiolabelled pB2I- 1 probe. The blots were
washed at high stringency as described by Church & Gilbert
(1984).
Computer analysis
The five CCP repeats of /821 (CCP repeat 1, residues 1-61 ; CCP
repeat 2, residues 62-119; CCP repeat 3, residues 120-182; CCP
repeat 4, residues 183-242; CCP repeat 5, residues 243-307) were
aligned by the computer program Alignment of Multiple Protein
Sequences (AMPS) (Barton & Stemnberg, 1987) with the mutation
data matrix of Dayhoff et al. (1983) with a bias of six added to
each term of the matrix and a break penalty of six.
RESULTS
PCR was used to generate a ,/21 transcript from HepG2 RNA.
A single 978 bp product was obtained by using synthetic
oligonucleotide primers and this was used to screen a human
liver cDNA library that was subcloned into the CDM8 expression
vector. Several hundred colonies hybridized specifically with the
978 bp PCR probe. Ten colonies were picked and were positive
on re-screening. All contained an approx. 1.1 kb-long
PstI-HindIII insert that hybridized specifically with the 978 bp
probe. The cDNA insert of one clone (pB2I-l) was sequenced
by plasmid double-strand sequencing with the use of two
oligonucleotides located 5' and 3' to the CDM8 subcloning site
(Estaller et al., 1991). Additional synthetic oligonucleotides based
on internal sequences were generated to determine the nucleotide
sequence from both strands. The sequencing strategy used is
shown in Fig. 1.
The complete nucleotide and deduced amino acid sequence of
clone pB2I-I is illustrated in Fig. 2. The clone pB2I-I encodes the
complete protein sequence of the mature human /32l. Further-
more, the cDNA insert contains 21 bp of the 5' untranslated
region followed by coding sequence for a 19-amino acid-residue
putative leader peptide starting with an ATG triplet. The coding
sequence for the mature protein (326 amino acid residues) is
978 bp long (beginning at base 79) and is followed by a TAA stop
codon. The 93 bp-long 3' untranslated region contains a putative
polyadenylation signal (AATAAA) 73 bp downstream from the
stop codon (see Fig. 2). Comparing the published protein
sequence (Lozier et al., 1984) with the deduced amino acid
sequence from clone pB2I-l, three major differences were found.
The cysteine at amino acid position 102 is substituted in the
cDNA-derived sequence by a serine residue, asparagine at
position 169 is replaced by a cysteine and the valine at position
247 is changed to a leucine residue, as indicated on Fig. 2.
Sequencing of the appropriate regions of six further clones
confirmed that in each case a serine was encoded at amino acid
5' ' 3'
I~~ pB21-1
I I l
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Fig. 1. Sequencing strategy
The cDNA insert of clone pB2I-l was sequenced by plasmid double-
strand sequencing using 5'- and 3'-oligonucleotides located in the
CDM8 subcloning site. Internal oligonucleotides were synthesized
for multiple sequencing from both strands. Arrows indicate the
extent and direction of DNA sequence determination.
position 102, and a cysteine at position 169. At position 247,
however, leucine (TTA) was found in six clones (including pB2I-
1) and valine (GTA) was found in one clone (pB2I-2).
The site of synthesis of /32I was investigated by Northern-blot
analysis. Total RNA was isolated from the cell lines HepG2,
Hela, Raji and Molt4 and also from U937 cells, which were
cultured for 3 days with and without phorbol 12-myristate 13-
acetate (30 ng/ml). A 10,ug portion of each RNA was separated
on a 1.2% (w/v) agarose gel, which was subsequently blotted
and hybridized with the 1.15 kb pB2I-l probe. A signal cor-
responding to an approx. 1.5 kb transcript was detected in
HepG2-derived RNA, whereas no signal was detected in the
RNA from the other cell lines (results not shown). The strong
hybridization signal after a short exposure (5 h) indicated a large
amount of /2I mRNA present in HepG2 cells. Even after long
exposure (2 days) it was not possible to detect any signal in the
other RNAs tested. The abundance of positive clones in the liver
cDNA library and the presence of /821 mRNA in the hepatoma
cell line indicate that hepatocytes are a major site of /321 synthesis.
DISCUSSION
The complete nucleotide sequence and derived amino acid
sequence for human /321 has been established by cDNA cloning
and sequencing. There are two major differences, both involving
cysteine residues, between the cDNA-derived amino acid se-
quence of /621 and that established by protein-sequencing
techniques (Lozier et al., 1984). The cysteine at position 102 is
replaced by a serine residue and asparagine- 169 is replaced by a
cysteine residue in the derived amino acid sequence. The two
changes involving cysteines occur in CCP repeats 2 and 3 of /321.
The CCP repeat is based on a consensus sequence with four
invariant cysteine residues disulphide-bonded in a pattern Cys
1-3 and Cys 2-4 (Day et al., 1989; Janatova et al., 1989; Day,
1991). In the protein sequence published by Lozier et al. (1984),
CCP repeat 2 had a cysteine residue additional to the consensus
cysteine residues and CCP repeat 3 had consensus Cys 3 missing.
Therefore CCP repeats 2 and 3 of /321 were unusual examples of
CCP repeats in general. It is unlikely that the differences involving
cysteine residues are polymorphisms, as these are structurally
important residues, and were probably incorrect assignments in
the protein sequence. However, the third difference noted, valine
to leucine at position 247, is likely to be a polymorphism: both
valine and leucine were found to be encoded in different clones
from the same cDNA library, suggesting that the DNA donor
was heterozygous.
A partial cDNA sequence for rat /821 has been published in
abbreviated format (Aoyama et al., 1989). In comparison with
the sequence shown in Fig. 2, a large segment, corresponding to
bases 88-232 of Fig. 2, appears to be missing from the rat clone.
The first 73 bases of the rat sequence align with nucleotide
residues 15-87 of Fig. 2, with 13 mismatches. This region
corresponds to the last seven nucleotide residues of the 5'
untranslated region, the entire signal sequence and the first two
amino acid residues of the mature protein. The rest of the rat
sequence aligns with nucleotide residues 232-1136 in Fig. 2, with
182 mismatches. Aoyama et al. (1989) suggested that rat /321 has
major differences from the human protein at the N-terminal end,
but this appears likely to have arisen from a cloning artifact
involving an approx. 145 bp deletion. The deletion does not
correspond to a complete domain at the protein level. The major
portion of the rat cDNA-derived amino acid sequence
corresponds to amino acid residues 52-326 of the human
sequence (Fig. 2). The rat and human sequences are 82.5 %
identical over this region, with all cysteine residues, including
position 169, conserved. Position 102 is also a serine residue in
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M I S P V L I L F S S F L C H V A T A G R T C
GGCCAGTGTGACTCATCCACAATGATTTCTCCAGTGCTCATCTTGTTCTCGAGTTTTCTCTGCCATGTTGCTATTGCAGGACGGACCTGT
10 20 30 40 50 60 70 80 90
10 20 30
P K P D D L P F S T V V P L K T F Y E P G E E I T Y S C K P
CCCAAGCCAGATGATTTACCATTTTCCACAGTGGTCCCGTTAAAAACATTCTATGAGCCAGGAGAAGAGATTACGTATTCCTGCAAGCCG
100 110 120 130 140 150 160 170 180
40 50 60
G Y V S R G G M R K F I C P L T G L W P I N T L K C T P R V
GGCTATGTGTCCCGAGGAGGGATGAGAAAGTTTATCTGCCCTCTCACAGGACTGTGGCCCATCAACACTCTGAAATGTACACCCAGAGTA
190 200 210 220 230 240 250 260 270
70 80 90
C P F A G I L E N G A V R Y T T F E Y P N T I S F S C N T G
TGTCCTTTTGCTGGAATCTTAGAAAATGGAGCCGTACGCTATACGACTTTTGAATATCCCAACACGATCAGTTTTTCTTGTAACACTGGG
280 290 300 310 320 330 340 350 360
C
100 4 110 120
F Y L N G A D S A K C T E E G K W S P E L P V C A P I I C P
TTTTATCTGAATGGCGCTGATTCTGCCAAGTGCACTGAGGAAGGAAAATGGAGCCCGGAGCTTCCTGTCTGTGCTCCCATCATCTGCCCT
370 380 390 400 410 420 430 440 450
130 140 150
P P S I P T F A T L R V Y K P S A G N N S L Y R D T A V F E
CCACCATCCATACCTACGTTTGCAACACTTCGTGTTTATAAGCCATCAGCTGGAAACAATTCCCTCTATCGGGACACAGCAGTTTTTGAA
460 470 480 490 500 510 520 530 540
N
160 4170 180
C L P Q H A M F G N D T I T C T T H G N W T K L P E C R E V
TGTTTGCCACAACATGCGATGTTTGGAAATGATACAATTACCTGCACGACACATGGAAATTGGACTAAATTACCAGAATGCAGGGAAGTA
550 560 570 580 590 600 610 620 630
190 200 210
K C P F P S R P D N G F V N Y P A K PT L Y Y K D K A T F G
AAATGCCCATTCCCATCAAGACCAGACAATGGATTTGTGAACTATCCTGCAAAACCAACACTTTATTACAAGGATAAAGCCACATTTGGC
640 650 660 670 680 690 700 710 720
220 230 240
C H D G Y S L D G P E E I E C T K L G N W S A M P S C K A S
TGCCATGATGGATATTCTCTGGATGGCCCGGAAGAAATAGAATGTACCAAACTGGGAAACTGGTCTGCCATGCCAAGTTGTAAAGCATCT
730 740 750 760 770 780 790 800 810
V
4 250 260 270
C K L P V K K A T V V Y Q G E R V K I Q E K F K N G M L H G
TGTAAATTACCTGTGAAAAAAGCCACTGTGGTGTACCAAGGAGAGAGAGTAAAGATTCAGGAAAAATTTAAGAATGGAATGCTACATGGT
820 830 840 850 860 870 880 890 900
280 290 300
D K V S F F C K N K E K K C S Y T E D A Q C I D G T I E V P
GATAAAGTTTCTTTCTTCTGCAAAAATAAGGAAAAGAAGTGTAGCTATACAGAGGATGCTCAGTGTATAGATGGCACTATCGAAGTCCCC
910 920 930 940 950 960 970 980 990
310 320
K C F K E H S S L A F W K T D A S D V K P C
AAATGCTTCAAGGAACACAGTTCTCTGGCTTTTTGGAAAACTGATGCATCCGATGTAAAGCCATGCTAAGGTGGTTTTCAGATTCCACAT
1000 1010 1020 1030 1040 1050 1060 1070 1080
AAAATGTCACACTTGTTTCTTGTTCATCCAAGGAACCTAATTGAAATTTAAA&I=GCTACTGAATTTAT
1090 1100 1110 1120 1130 1140 lS10
Fig. 2. Nucleotide sequence and deduced amino acid sequence of 121
The cDNA-derived amino acid sequence is shown. The putative 19-amino acid-residue leader sequence starting with a methionine residue is
underlined. Vertical arrows indicate the three amino acid differences at positions 102 (Cys-.Ser), 169 (Asn-.Cys) and 247 (Val-aLeu) when
compared with the protein sequence published by Lozier et al. (1984). The possible polyadenylation signal is double-underlined.
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the rat sequence, and the 'polymorphic' position 247 is a leucine
residue.
The cDNA-deduced amino acid sequence establishes CCP
repeats 2 and 3 off821 as being typical members of the CCP repeat
superfamily, each having four cysteine residues. A new alignment
of the repeats in I2?I is shown in Fig. 3. CCP repeats 2 and 3 have
one disulphide bridge mapped (Cys 2-4 in both cases), and it is
very likely that they will have the normal Cys 1-3 linkages (see
Fig. 3). In contrast with the first four CCP repeats of f82I, which
are typical examples of this domain, the fifth repeat is the most
aberrant member of the CCP superfamily. Nevertheless, it fulfils
the criteria for membership of this family (Patthy, 1987). In CCP
repeat 5 there is an extra non-consensus cysteine residue,
disulphide-linked to consensus Cys 2 (see Fig. 3). It seems likely
that the consensus Cys 1-3 disulphide linkage will form normally
and that consensus Cys 4 is linked to the cysteine residue at the
C-terminal end of the protein (see Fig. 3). A CCP repeat from
complement Factor H has been shown to be an independently
folding domain and its secondary structure has been determined
by two-dimensional n.m.r. spectroscopy (Barlow et al., 1991).
Although CCP repeat 5 has a unique disulphide bond organiz-
ation and an additional C-terminal region, it is likely that these
differences can be accommodated within the secondary-structure
model of the CCP domain.
fl21 in association with negatively charged phospholipids has
been identified as an autoantigen involved in certain autoimmune
disorders (e.g. systemic lupus erythematosus) (McNeil et al.,
1990; Galli et al., 1990). In this regard CCP repeat 5 of human
and rat fi21 contains a highly positively charged sequence
KNKEKK (residues 282-287) that is constrained by a disulphide
bridge (see Fig. 3). On the basis of the secondary structure model
for the CCP domain (Barlow et al., 1991), this motif is likely to
be present as a surface-exposed turn. Therefore it is a possibility
that this sequence may constitute the binding site for negatively
charged phospholipids.
In the original sequence paper by Lozier et al. (1984), five
potential asparagine-linked glycosylation sites were proposed.
As asparagine- 169 is replaced by a cysteine residue in the cDNA-
derived protein sequence, this can no longer constitute a sugar-
attachment site. Work by Walsh et al. (1990) suggests that the
potential carbohydrate-attachment sites are all utilized and the
sugars are of bi- and tri-antennary type.
The cloning and sequencing of /32I allows the use of protein-
engineering techniques to investigate its physiological function.
There is a vital need to understand the involvement of /321 in
autoimmune disorders such as systemic lupus erythematosus. In
this regard, further work is required to express the fifth CCP
repeat, together with the C-terminal portion, to assess whether
the proposed phospholipid interaction site of /321 is present in this
region.
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